Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2014

01-02-2014 | Letter

Angiogenic factors in sepsis: are we ready for the new therapeutic era?

Authors: Ru-Yuan Zhang, Hong Zhang, Jie Huang, Hong-Ping Qu, Yao-Qing Tang

Published in: Critical Care | Issue 1/2014

Login to get access

Excerpt

Recently, Fiusa and colleagues [1] described that a high angiopoietin (Ang)-2/Ang-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. Although this study failed to detect a statistically significant difference in the levels of vascular endothelial growth factor (VEGF) between both outcome groups, the observed increased Ang-2 concentrations and Ang-2/Ang-1 ratio in the febrile neutropenia subgroup of patients with septic shock address the concept that angiogenic factors could be a promising therapeutic target in sepsis. …
Literature
1.
Fiusa MM, Costa-Lima C, de Souza GR, Vigorito AC, Aranha FJ, Lorand-Metze I, Annichino-Bizzacchi JM, De Souza CA, De Paula EV: A high angiopoietin-2/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. Crit Care 2013, 17: R169. 10.1186/cc12848CrossRef
2.
Jeong SJ, Han SH, Kim CO, Choi JY, Kim JM: Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis. Crit Care 2013, 17: R97. 10.1186/cc12742PubMedCentralCrossRefPubMed
3.
Ziegler T, Horstkotte J, Schwab C, Pfetsch V, Weinmann K, Dietzel S, Rohwedder I, Hinkel R, Gross L, Lee S, Hu J, Soehnlein O, Franz WM, Sperandio M, Pohl U, Thomas M, Weber C, Augustin HG, Fassler R, Deutsch U, Kupatt C: Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J Clin Invest 2013.
4.
Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS: Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009, 27: 3557-3565. 10.1200/JCO.2008.19.6683CrossRefPubMed
Metadata
Title
Angiogenic factors in sepsis: are we ready for the new therapeutic era?
Authors
Ru-Yuan Zhang
Hong Zhang
Jie Huang
Hong-Ping Qu
Yao-Qing Tang
Publication date
01-02-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc13710

Other articles of this Issue 1/2014

Critical Care 1/2014 Go to the issue

Research

Variation in the use of renal replacement therapy in patients with septic shock: a substudy of the prospective multicenter observational FINNAKI study

Research

Comparative evaluation of three interfaces for non-invasive ventilation: a randomized cross-over design physiologic study on healthy volunteers

Research

Multiple gene-to-gene interactions in children with sepsis: a combination of five gene variants predicts outcome of life-threatening sepsis

Viewpoint

Renal recovery

Review

Mechanical ventilation during extracorporeal membrane oxygenation

Research

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis